Airway Smooth Muscle |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
ABSTRACT |
|---|
|
|
|---|
The airway smooth muscle cell can contract; relax; participate in allergic and inflammatory responses by expressing adhesion molecules, releasing cytokines, and producing matrix proteins and proteases; and, as has been reported, undergo migration. These properties enable the muscle cell to be a key component in the airway wall remodeling that accompanies persistent asthma. Evidence is emerging that identifies the pivotal steps in the signal transduction pathways that lead to the excessive proliferation of the muscle observed in vitro in airway smooth muscle cells from subjects with asthma. The contractile, biochemical, and growth characteristics of muscle from allergic subjects are different from those of nonallergic subjects. In addition, the allergic response impacts on the extracellular matrix in which the muscle is embedded, by altering the profile of matrix proteins released. Once the relationships between allergy and inflammation of the smooth muscle and its extracellular matrix are better defined, opportunities to prevent or reverse airway remodeling will become available.
| |
INTRODUCTION |
|---|
|
|
|---|
The concept of the contribution of the airway smooth muscle cell to the pathophysiological changes that occur in asthma has markedly changed. From playing a passive role as a structural cell, implicated merely in the contraction producing immediate airway narrowing, the airway smooth muscle cell is now acknowledged as an active participant in the inflammatory and allergic events that accompany persistent asthma. This is based on the observations that this cell (1) undergoes proliferation in response to many growth factors and cytokines, resulting in an increase in muscle volume that is in part due to hyperplasia, (2) produces and releases a number of cytokines (1), (3) is capable of expressing on the cell surface adhesion molecules that engage inflammatory cells, which in turn results in the further elaboration of cytokines and increases in proliferation (2, 3), and (4) produces extracellular matrix proteins that can profoundly influence muscle cell function (4).
| |
AIRWAY SMOOTH MUSCLE AND ALLERGY |
|---|
|
|
|---|
The airway smooth muscle has the potential to contribute to
and be influenced by the allergic response. This is true of both contractility and growth. Exposure of human bronchial segments to allergic asthmatic serum (passive sensitization) produces increases in contraction and decreases in relaxation responses to a number of agonists (5). Bronchial tissue which
contracts in response to the application of allergen (i.e., which
is "sensitized"
a response that is likely to be the airway in
vitro equivalent of the skin prick test), contracts more in response to histamine when in the presence of mast cell-derived
tryptase than does tissue that does not contract in response to
allergen (nonsensitized) (14). Sensitized airway smooth muscle contains more myosin light chain kinase than does nonsensitized muscle (15) and more mast cells are observed in the
muscle layer of sensitized bronchi (16). Whether this translates to altered contractility or growth is not known. When human airway smooth muscle cells in culture are exposed to allergic serum and challenged with allergen, there is increased
protein expression of the oncogenes c-fos and c-jun and cycling of the cells as measured by incorporation of tritiated thymidine (13). Exposure of muscle cells to allergic serum also specifically increases the release of some matrix proteins (4). Clearly, therefore, there is an important interaction between the allergic response and the properties of the muscle cell that are relevant to asthmatic airway wall remodeling.
| |
AIRWAY SMOOTH MUSCLE PROLIFERATION |
|---|
|
|
|---|
Since culture of human airway smooth muscle cells has become possible, there has been considerable focus on elucidating the signal transduction pathways leading to proliferation
(1). The effects of mitogens are mediated through at least two
distinct receptor systems: tyrosine kinase-linked receptors (such
as platelet-derived growth factor, epidermal derived growth
factor, and basic fibroblast growth factor) and G protein-coupled receptors (GPCRs) (stimulated by thrombin). Downstream of these two systems, activation of the Shc-Grb2-Sos
complex occurs or phosphatidylinositol (PI) 3 kinase is activated. This leads to activation of p21 Ras, and, after activation, active Ras binds to GTP. Raf-1 is then activated and translocates to the plasma membrane, where it phosphorylates
mitogen-activated protein kinase kinase (MEK). A group of
key regulators of growth, the mitogen-activated protein (MAP)
kinases, is then stimulated. Evidence is accumulating that one
of the MAP kinases, extracellular signal-regulated protein kinase (ERK), plays a crucial role in human airway smooth muscle (HASM) cell growth (17). Mitogens activating both tyrosine kinase and GPCRs cause upregulation of active ERK
(Figure 1) and this is associated with an increase in thymidine
uptake, an indicator of cell proliferation. Inhibition of MEK
with specific antagonists such as UO126 or use of an antisense sequence directed to ERK decreases ERK activation and also
inhibits thymidine incorporation (17). Activated ERK activates transcription factors such as c-Jun, c-Fos, and c-Myc in
the nucleus and this may occur via activation of p90 ribosomal
S6 kinase (Figure 1). This would suggest that ERK activation
is necessary and sufficient for proliferation of HASM cells.
However, others have reported the existence of ERK-independent pathways to proliferation that are mediated via stimulation of PI 3-kinase (18). In addition, there is synergy between the two pathways (18). Inflammatory and contractile
mediators that signal through G protein-coupled receptors
and that do not themselves produce proliferation can significantly augment growth occurring through the receptor tyrosine kinase pathway. Although ERK and perhaps PI 3-kinase
may afford opportunities for therapeutic targeting, other steps
in the signaling pathway may need to be inhibited. Protein kinase C (PKC)-
, one of the atypical isoforms of this enzyme,
is specifically increased when HASM cells are stimulated with
mitogens (19). Moreover, an antisense oligonuceotide directed to
PKC-
significantly inhibits proliferation of HASM cells induced
by platelet-derived growth factor (PDGF) (20). PKC-
can be
activated by PI 3-kinase and by Ras and PKC-
may directly
activate Raf-1. The relationship between ERK, PI 3-kinase,
and PKC-
in the proliferative pathway in human airway
smooth muscle cells and, in particular, in asthmatic cells remains to be determined, especially if targeted inhibition of
proliferation to prevent or reverse remodeling is to be attempted.
|
| |
AIRWAY SMOOTH MUSCLE AND THE EXTRACELLULAR MATRIX |
|---|
|
|
|---|
Although several studies have demonstrated an increase in
the amount of smooth muscle in the airway wall, this is not the only component of remodeling, that is, architectural/structural changes, that can impact on airway function. The extracellular matrix (ECM), in particular that component which surrounds
and embeds the airway smooth muscle, plays a pivotal role in
modulating the proliferative and contractile properties of the
smooth muscle. The ECM is an intricate network of macromolecules that have the potential to influence migration, proliferation and differentiation (21, 22) of human airway smooth
muscle. It can also influence the distribution and adhesion of
inflammatory cells, fluid balance, and elasticity and act as an
inflammatory mediator reservoir (23). In the airways of subjects with asthma, there is an increase in the amount of collagen I, III, and V, fibronectin, tenascin, hyaluronan, versican,
and laminin
2/
2 (reviewed in Johnson and coworkers [4])
and a decrease in collagen IV and elastin (24). Changes in
ECM deposition within the airways of subjects with asthma
may lead, or contribute, to the development of bronchial hyperresponsiveness. The causes of the change in matrix deposition are unknown; however, plasma leakage from the microvasculature as part of allergic and inflammatory processes
may play a role. HASM cells in culture produce fibronectin,
perlecan, elastin, laminin
1,
1,
2, and
1, thrombospondin,
chondroitin sulfate, collagen types I, III, IV, and V, versican,
and decorin. When these cells are exposed to allergic serum
from subjects with asthma, production of fibronectin, laminin
1 chain, perlecan and chondroitin sulfate is increased compared with cells exposed to nonallergic serum from patients without asthma (4). Interestingly, these increases in specific proteins are not inhibited by prior exposure to either corticosteroids or leukotriene antagonists. The changes in the ECM
in the asthmatic airway wall could also result from decreased
activity of degrading enzymes
the matrix metalloproteinases
(MMPs) or upregulation of the tissue-specific inhibitors of
metalloproteinases (TIMPs). The influence of the allergic response is also apparent on these enzymes. HASM cells secrete
the two gelatinases MMP-2 and MMP-9 as well as TIMP-1 but
not TIMP-2 or -3. Exposure of asthmatic HASM cells to asthmatic serum increases the activity of MMP-9 and decreases
the expression and activity of MMP-2. Thus the inflammatory/ allergic response with associated vascular leakage and subsequent exposure of muscle cells to serum components may contribute to changes in the extracellular matrix (25). These
changes have the potential to produce profound alterations in
the properties of the smooth muscle that lies within it. Allergic
serum contains many potentially active components, however,
and which of these is responsible for the observed increases in
specific matrix proteins is not known. Attempts to attribute a
role to the high concentration of IgE that characterizes the allergic serum have so far been unsuccessful (4).
| |
AIRWAY SMOOTH MUSCLE CELL MIGRATION |
|---|
|
|
|---|
The similarities between the remodeling that occurs in the
vasculature as an accompaniment to atherosclerosis and that
in airways in asthma has been noted for some time (26). Both
involve chronic inflammatory processes in hollow tubes and
both are amenable to intervention. Until recently, one of the
major differences between the two resided in the fact that one
of the pivotal events in the remodeled vessel is the early migration of muscle cells from the media to form a neointima underneath the endothelium. Chemotaxis was first studied in
human cells in 1976 by Postlethwaite and coworkers (27). Fibroblasts were shown to migrate through 8-µm pores in a
Boyden chamber toward a compartment containing a chemotactic agent, and the same procedure was used to demonstrate that PDGF is chemotactic for aortic smooth muscle cells.
Skinner and coworkers (28) showed that migration of human
vascular cells was dependent on the extracellular matrix in
that the presence of the
2
1 integrin complex was necessary.
Mukhina and coworkers (29) reported that human airway
smooth muscle cells in culture are capable of migration, particularly in response to urokinase plasminogen activator. Plasminogen activators are of two types: urokinase plasminogen
activator (uPA or urokinase), which is secreted by many cell
types, and tissue-type plasminogen activator (tPA). Of these,
uPA is implicated in cell migration and proliferation (Figure
2). These actions are mediated via the high-affinity cell surface
receptor - uPA receptor (uPAR), which is also designated CD87. The uPAR system is also implicated in the chemotactic
responses initiated by growth factors that are linked to receptor tyrosine kinase. The uPAR is anchored to the extracellular
membrane by a membrane lipid anchor and, because it does
not cross the cell membrane, its intracellular actions may be
mediated via integrins (30) and also the lipoprotein receptor
(LPR). Upregulation of the uPA/uPAR system can occur in
response to a variety of growth factors and cytokines (31) and
the signal transduction events that mediate this are thought to
be the classic mitogenic pathway involving phospholipase D,
PKC, Ras, Raf, and ERK. Mukhina and coworkers (29) found
that human airway smooth muscle cells migrate via an interaction involving the binding of the uPA kringle domain to the
cell surface membrane and the association of uPA with the urokinase receptor. The significance of this finding that airway smooth muscle cells migrate lies in the fact that, just as occurs in remodeled vessels, in which muscle cells migrate to form a neointima underneath the endothelium, airway smooth muscle cells may migrate in response to a number of factors
perhaps arising from the injured epithelium or the presence of inflammatory mediators and growth factors, to take up a
position underneath the epithelium. It is possible that myofibroblasts, which have been observed in this position in the
asthmatic airway, could be muscle cells that have migrated lumenally. Whether this is true in the remodeled airway, and
whether there are significant functional sequelae, requires further investigation.
|
| |
ASTHMATIC AIRWAY SMOOTH MUSCLE CELLS |
|---|
|
|
|---|
Until more recently it has been difficult to obtain and culture
airway smooth muscle cells from subjects with asthma. However, this opportunity has now arisen. We hypothesized that
there is an intrinsic abnormality of the smooth muscle cell that
contributes to the increased amount of smooth muscle in the
asthmatic airway wall and that we would detect this abnormality in our culture system. Indeed, asthmatic airway smooth
muscle cells grow at approximately twice the rate of cells from
subjects without asthma (32). It is now crucial to determine at
what point(s) in the signal transduction pathway this abnormality occurs. There is preliminary evidence that activation of
ERK is altered in asthmatic cells. Although basal ERK activity
is surprisingly lower in asthmatic cells, peak ERK activity in response to stimulation with a low concentration of mitogen is
greatly increased over that in cells from subjects without
asthma (33). Whether any abnormality exists in the PKC-
or
the PI 3-kinase pathways is not known.
Differences between asthmatic and nonasthmatic airway
smooth muscle cells in the effects of the long-acting
-agonist
formoterol and the corticosteroid budesonide on proliferation
have also been observed in preliminary experiments (34).
Whereas both drugs produce inhibition of mitogenesis in nonasthmatic cells, and formoterol inhibits growth in asthmatic
cells, budesonide does not cause inhibition in asthmatic cells.
Thus there may be an intrinsic abnormality in endogenous inhibitory pathways in the asthmatic airway smooth muscle that
could contribute to increased proliferation.
Exactly how remodeling in the airways, and in particular those changes that occur in relation to the smooth muscle, relate to changes in lung function is not known. What is known, however, is that increased amounts of smooth muscle are likely to lead to exaggerated airway narrowing. Moreover, patients differ in the degree to which their airflow limitation is reversible. Whether this heterogeneity is related to the presence of airway wall remodeling remains to be investigated.
| |
CONCLUSIONS AND FUTURE RESEARCH |
|---|
|
|
|---|
Now that it is possible to study airway smooth muscle cells from subjects with asthma, we have an opportunity to define the exact abnormality in the signal transduction pathways that lead to excessive proliferation. Further valuable information may be gained by examining an additional property of airway smooth muscle cells, namely, migration. As a consequence of this, it will be possible to devise strategies to intervene or reverse the processes that lead to airway wall remodeling. In addition, the mechanisms underlying the relationship between the allergic response and alteration in the properties of smooth muscle require elucidation.
| |
Footnotes |
|---|
Correspondence and requests for reprints should be addressed to Judith L. Black, Department of Pharmacology, University of Sydney, Sydney NSW 2006, Australia. E-mail: judblack{at}pharmacol.usyd.edu.au
(Received in original form June 15, 2001 and accepted in revised form July 13, 2001).
Acknowledgments: The authors acknowledge the collaborative efforts of Dr. Greg King, and of the Cardiopulmonary Transplant Team at St. Vincent's Hospital.
Supported by the NH&MRC, Australia; the Medical Foundation of the University of Sydney; and AstraZeneca, Sweden.
| |
References |
|---|
|
|
|---|
1. Hirst SJ. Airway smooth muscle as a target for asthma. Clin Exp Allergy 2000; 30: 54-59 .
2.
Lazaar AL,
Albelda SM,
Pilewsky JM,
Brennan B,
Pure E,
Panettieri RA.
T lymphocytes adhere to airway smooth muscle cells via integrins
and CD44 and induce smooth muscle cell DNA synthesis.
J Exp Med
1994;
180:
807-816
3.
Lazaar AL,
Amrani Y,
Panettieri RA,
Fanslow WC,
Albelda SM,
Pure E.
CD40-mediated signal transduction in human airway smooth muscle.
J Immunol
1998;
161:
3120-3127
4.
Johnson PRA,
Black JL,
Carlin S,
Underwood PA.
The production of
extracellular matrix proteins by human passively sensitized airway
smooth muscle cells in culture
the effect of beclomethasone.
Am J
Respir Crit Care Med
2000;
162:
1-7
5. Black JL, Marthan R, Armour CL, Johnson PRA. Sensitization alters contractile responses and calcium influx in human airway smooth muscle. J Allergy Clin Immunol 1989; 84: 440-447 [Medline].
6. Marthan R, Crevel H, Guenard H, Savineau JP. Responsiveness to histamine in human sensitized airway smooth muscle. Respir Physiol 1992; 90: 239-250 [Medline].
7. Ben-Jebria A, Marthan R, Rossetti M, Savineau JP. Effect of passive sensitization on the mechanical activity of human isolated bronchial smooth muscle induced by substance P, neurokinin A, and VIP. Br J Pharmacol 1993; 109: 131-136 [Medline].
8.
Mitchell RW,
Ruhlmann E,
Magnussen H,
Leff AR,
Rabe KF.
Passive
sensitization of human bronchi augments smooth muscle shortening
velocity and capacity.
Am J Physiol
1994;
267:
L218-L222
9. Villanove X, Marthan R, Johnson PRA, Tunon de Lara JM, McKay KO, Alouan LA, Armour CL, Black JL. Sensitization decreases relaxation in human isolated airways. Am Rev Respir Dis 1993; 148: 107-112 [Medline].
10. Watson N, Ruhlmann E, Magnussen H, Rabe KF. Histamine hypersensitivity induced by passive sensitization of human bronchus: effect of serum IgE depletion. Clin Exp Allergy 1998; 28: 679-685 [Medline].
11. Watson N, Bodtke K, Coleman RA, Dent G, Morton BE, Ruhlmann E, Magnussen H, Rabe KF. Role of IgE in hyperresponsiveness induced by passive sensitization of human airways. Am J Respir Crit Care Med 1997; 155: 839-844 [Abstract].
12.
Song P,
Milanese M,
Crimi E,
Rehder K,
Brusasco V.
Allergen challenge of passively sensitized human bronchus alters M2 and
2 receptor function.
Am J Respir Crit Care Med
1997;
155:
1230-1234
[Abstract].
13.
Black JL.
What determines asthma phenotype
is it the interaction between allergy and the smooth muscle?
Am J Respir Crit Care Med
2000;
161:
S207-S210
14. Johnson PRA, Ammit AJ, Carlin SM, Armour CL, Caughey GH, Black JL. Mast cell tryptase potentiates histamine-induced contraction in human sensitized bronchus. Eur Respir J 1997; 10: 38-43 [Abstract].
15. Ammit AJ, Armour CL, Black JL. Myosin light chain kinase content is increased in human sensitized airway smooth muscle. Am J Respir Crit Care Med 2000; 16: 257-263 .
16. Ammit AJ, Bekir SS, Johnson PRA, Hughes JM, Armour CL, Black JL. Mast cell numbers are increased in the smooth muscle of human sensitized isolated bronchi. Am J Respir Crit Care Med 1997; 155: 1123-1129 [Abstract].
17. Lee J-H, Johnson PRA, Roth M, Hunt NH, Black JL. Extracellular signal regulated protein kinase activation and mitogen-induced cell proliferation in human airway smooth muscle cells. Am J Physiol 2001; 280: L1019-L1029 .
18.
Krymskaya VP,
Orsini MJ,
Esterhas AJ,
Brodbeck KC,
Benovic JL,
Panettieri RA Jr,,
Penn RB.
Mechanisms of proliferation synergy by
receptor tyrosine kinase and G protein coupled receptor activation in
human airway smooth muscle.
Am J Respir Cell Mol Biol
2000;
23:
546-554
19.
Carlin S,
Yang KXF,
Donnelly R,
Black JL.
Protein kinase C isoforms in
human airway smooth muscle cells
a role for PKC-
in proliferation.
Am J Physiol
1999;
276:
506-512
.
20.
Carlin S, Cook DI, Poronnik P, Biden T, Carpenter L, Johnson PRA,
Black JL An antisense to protein kinase C-
inhibits proliferation of
human airway smooth muscle cells Am J Resp Cell Mol Biol 2000;23:
555-559.
21.
Akiyama SK,
Yamada SS,
Chen WT,
Yamada KM.
Analysis of fibronectin receptor function with monoclonal antibodies: roles in cell adhesion, migration, matrix assembly, and cytoskeletal organization.
J Cell
Biol
1989;
109:
863-875
22. Erle DJ, Pytela R. How do integrins integrate? The role of cell adhesion receptors in differentiation and development. Am J Respir Cell Mol Biol 1992; 6: 459-460 .
23.
Vignola AM,
Chanez P,
Chiappara G,
Merendino A,
Pace E,
Rizzo A,
La Rocca AM,
Bellia V,
Bonsignore G,
Bousquet J.
Transforming
growth factor-
expression in mucosal biopsies in asthma and chronic
bronchitis.
Am J Respir Crit Care Med
1997;
156:
591-599
24. Bousquet J, Chanez P, Lacoste JY, White R, Vic P, Godard P, Michel FB. Asthma: a disease remodeling the airways. Allergy 1992; 47: 3-11 [Medline].
25. Johnson PRA, Black JL, Perruchoud AP, Tamm M, Roth M. Atopic asthmatic serum alters expression of matrix metalloproteinases in human bronchial smooth muscle cells. Am J Respir Crit Care Med 1999; 159: A260 .
26. Page C, Black JL, editors. Airways and vascular remodelling in asthma and cardiovascular disease. London: Academic Press; 1994.
27.
Postlethwaite A,
Snyderman R,
Kang A.
The chemotactic attraction of
human fibroblasts to a lymphocyte-derived factor.
J Exp Med
1976;
144:
1188-1203
28.
Skinner M,
Raines E,
Ross R.
Dynamic expression of
1
1 and
2
1 integrin receptors by human vascular smooth muscle cells.
Am J Pathol
1994;
145:
1070-1081
[Abstract].
29.
Mukhina S,
Stepanova V,
Traktouev D,
Poliakov A,
Beabealashvilly RM,
Minashkin M,
Shevelev A,
Tkachuk V.
The chemotactic action
of urokinase on smooth muscle cells is dependent on its kringle domain.
J Biol Chem
2000;
275:
16450-16458
30.
Ghosh S,
Brown R,
Jones J,
Ellerbrock S,
Stack M.
Urinary-type plasminogen activator (uPA) expression and uPA receptor localization are
regulated by
3
1 integrin in oral keratinocytes.
J Biol Chem
2000;
275:
23869-23876
31. Strand K, Murray J, Aziz S, Ishida A, Rahman S, Patel Y, Cardona C, Hammond W, Savidge G, Wijelath E. Induction of the urokinase plasminogen activator system by oncostatin M promotes endothelial migration. J Cell Biochem 2000; 79: 239-248 [Medline].
32.
Johnson PRA,
Roth M,
Tamm M,
Hughes JM,
Ge Q,
Burgess JK,
King G,
Black JL.
Airway smooth muscle cell proliferation is increased in
asthma.
Am J Respir Crit Care Med
2001;
164:
474-477
33. Lee JH, Johnson PRA, Hunt NH, Roth M, Black JL. Extracellular signal regulated kinase (ERK) activation is increased in smooth muscle cells from asthmatic patients. Am J Respir Crit Care Med 2001; 163: A269 .
34.
Johnson PRA,
Black JL,
Tamm M,
King G,
Ge Q,
Au W,
Roth M.
Proliferation of asthmatic and non asthmatic airway smooth muscle cells
in culture
effect of formoterol and budesonide.
Am J Respir Crit
Care Med
2001;
163:
A270
.
This article has been cited by other articles:
![]() |
M. Hirakawa, Y. Karashima, M. Watanabe, C. Kimura, Y. Ito, and M. Oike Protein Kinase A Inhibits Lysophosphatidic Acid-Induced Migration of Airway Smooth Muscle Cells J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 1102 - 1108. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. H. Kariyawasam, M. Aizen, J. Barkans, D. S. Robinson, and A. B. Kay Remodeling and Airway Hyperresponsiveness but Not Cellular Inflammation Persist after Allergen Challenge in Asthma Am. J. Respir. Crit. Care Med., May 1, 2007; 175(9): 896 - 904. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Choe, P. H. S. Sporn, and M. A. Swartz Extracellular Matrix Remodeling by Dynamic Strain in a Three-Dimensional Tissue-Engineered Human Airway Wall Model Am. J. Respir. Cell Mol. Biol., September 1, 2006; 35(3): 306 - 313. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Joubert, S. Lajoie-Kadoch, I. Labonte, A. S. Gounni, K. Maghni, V. Wellemans, J. Chakir, M. Laviolette, Q. Hamid, and B. Lamkhioued CCR3 Expression and Function in Asthmatic Airway Smooth Muscle Cells J. Immunol., August 15, 2005; 175(4): 2702 - 2708. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Citro, S. Ravasi, G. E. Rovati, and V. Capra Thromboxane Prostanoid Receptor Signals Through Gi Protein to Rapidly Activate Extracellular Signal-Regulated Kinase in Human Airways Am. J. Respir. Cell Mol. Biol., April 1, 2005; 32(4): 326 - 333. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. R. Tormanen, L. Uller, C. G. A. Persson, and J. S. Erjefalt Allergen Exposure of Mouse Airways Evokes Remodeling of both Bronchi and Large Pulmonary Vessels Am. J. Respir. Crit. Care Med., January 1, 2005; 171(1): 19 - 25. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. K. Jeffery Remodeling and Inflammation of Bronchi in Asthma and Chronic Obstructive Pulmonary Disease Proceedings of the ATS, November 1, 2004; 1(3): 176 - 183. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Panettieri Jr. Effects of Corticosteroids on Structural Cells in Asthma and Chronic Obstructive Pulmonary Disease Proceedings of the ATS, November 1, 2004; 1(3): 231 - 234. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Deng, N. J. Fairbank, B. Fabry, P. G. Smith, and G. N. Maksym Localized mechanical stress induces time-dependent actin cytoskeletal remodeling and stiffening in cultured airway smooth muscle cells Am J Physiol Cell Physiol, August 1, 2004; 287(2): C440 - C448. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.T. Holgate Lessons learnt from the epidemic of asthma QJM, May 1, 2004; 97(5): 247 - 257. [Full Text] [PDF] |
||||
![]() |
K. Shinagawa and M. Kojima Mouse Model of Airway Remodeling: Strain Differences Am. J. Respir. Crit. Care Med., October 15, 2003; 168(8): 959 - 967. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Goncharova, C. K. Billington, C. Irani, A. V. Vorotnikov, V. A. Tkachuk, R. B. Penn, V. P. Krymskaya, and R. A. Panettieri Jr. Cyclic AMP-Mobilizing Agents and Glucocorticoids Modulate Human Smooth Muscle Cell Migration Am. J. Respir. Cell Mol. Biol., July 1, 2003; 29(1): 19 - 27. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Benayoun, A. Druilhe, M.-C. Dombret, M. Aubier, and M. Pretolani Airway Structural Alterations Selectively Associated with Severe Asthma Am. J. Respir. Crit. Care Med., May 15, 2003; 167(10): 1360 - 1368. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Parameswaran, G. Cox, K. Radford, L. J. Janssen, R. Sehmi, and P. M. O'Byrne Cysteinyl Leukotrienes Promote Human Airway Smooth Muscle Migration Am. J. Respir. Crit. Care Med., September 1, 2002; 166(5): 738 - 742. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. TOBIN Asthma, Airway Biology, and Nasal Disorders in AJRCCM 2001 Am. J. Respir. Crit. Care Med., March 1, 2002; 165(5): 598 - 618. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Proc. Am. Thorac. Soc. | Am. J. Respir. Cell Mol. Biol. |